Logo image of VRNA

VERONA PHARMA PLC - ADR (VRNA) Stock Fundamental Analysis

NASDAQ:VRNA - Nasdaq - US9250501064 - ADR - Currency: USD

67.96  +3.77 (+5.87%)

After market: 68.25 +0.29 (+0.43%)

Fundamental Rating

2

Taking everything into account, VRNA scores 2 out of 10 in our fundamental rating. VRNA was compared to 194 industry peers in the Pharmaceuticals industry. While VRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. VRNA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VRNA had negative earnings in the past year.
In the past year VRNA has reported a negative cash flow from operations.
In the past 5 years VRNA always reported negative net income.
In the past 5 years VRNA always reported negative operating cash flow.
VRNA Yearly Net Income VS EBIT VS OCF VS FCFVRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

VRNA has a Return On Assets (-40.26%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -117.80%, VRNA is doing worse than 61.62% of the companies in the same industry.
Industry RankSector Rank
ROA -40.26%
ROE -117.8%
ROIC N/A
ROA(3y)-24.63%
ROA(5y)-35.6%
ROE(3y)-29.72%
ROE(5y)-43.88%
ROIC(3y)N/A
ROIC(5y)N/A
VRNA Yearly ROA, ROE, ROICVRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

VRNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRNA Yearly Profit, Operating, Gross MarginsVRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

VRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VRNA has been increased compared to 1 year ago.
VRNA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VRNA is higher compared to a year ago.
VRNA Yearly Shares OutstandingVRNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
VRNA Yearly Total Debt VS Total AssetsVRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 11.07 indicates that VRNA is not in any danger for bankruptcy at the moment.
VRNA has a Altman-Z score of 11.07. This is amongst the best in the industry. VRNA outperforms 86.49% of its industry peers.
VRNA has a Debt/Equity ratio of 0.92. This is a neutral value indicating VRNA is somewhat dependend on debt financing.
The Debt to Equity ratio of VRNA (0.92) is worse than 72.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Altman-Z 11.07
ROIC/WACCN/A
WACC9.04%
VRNA Yearly LT Debt VS Equity VS FCFVRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

VRNA has a Current Ratio of 13.03. This indicates that VRNA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VRNA (13.03) is better than 87.03% of its industry peers.
VRNA has a Quick Ratio of 12.88. This indicates that VRNA is financially healthy and has no problem in meeting its short term obligations.
VRNA has a Quick ratio of 12.88. This is amongst the best in the industry. VRNA outperforms 85.95% of its industry peers.
Industry RankSector Rank
Current Ratio 13.03
Quick Ratio 12.88
VRNA Yearly Current Assets VS Current LiabilitesVRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

2

3. Growth

3.1 Past

VRNA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -193.94%.
The Revenue has grown by 1122.61% in the past year. This is a very strong growth!
EPS 1Y (TTM)-193.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.11%
Revenue 1Y (TTM)1122.61%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

VRNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-149.3%
EPS Next 2Y34.91%
EPS Next 3Y67.95%
EPS Next 5Y39.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VRNA Yearly Revenue VS EstimatesVRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
VRNA Yearly EPS VS EstimatesVRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRNA Price Earnings VS Forward Price EarningsVRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300 -400 -500

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRNA Per share dataVRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as VRNA's earnings are expected to grow with 67.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.91%
EPS Next 3Y67.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERONA PHARMA PLC - ADR

NASDAQ:VRNA (2/21/2025, 8:00:01 PM)

After market: 68.25 +0.29 (+0.43%)

67.96

+3.77 (+5.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)02-27 2025-02-27/bmo
Inst Owners71.35%
Inst Owner Change2.35%
Ins Owners5.81%
Ins Owner Change-8.15%
Market Cap5.56B
Analysts85.33
Price Target68.68 (1.06%)
Short Float %12.34%
Short Ratio6.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-101.13%
Min EPS beat(2)-192.46%
Max EPS beat(2)-9.8%
EPS beat(4)1
Avg EPS beat(4)-65.36%
Min EPS beat(4)-192.46%
Max EPS beat(4)32.13%
EPS beat(8)3
Avg EPS beat(8)-28.52%
EPS beat(12)6
Avg EPS beat(12)-18.23%
EPS beat(16)9
Avg EPS beat(16)-2.78%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)43.26%
PT rev (3m)46.98%
EPS NQ rev (1m)34.02%
EPS NQ rev (3m)34.02%
EPS NY rev (1m)23.06%
EPS NY rev (3m)1.8%
Revenue NQ rev (1m)98.11%
Revenue NQ rev (3m)98.11%
Revenue NY rev (1m)13.47%
Revenue NY rev (3m)80.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 988.84
P/FCF N/A
P/OCF N/A
P/B 42.62
P/tB 42.8
EV/EBITDA N/A
EPS(TTM)-1.94
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0.07
BVpS1.59
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.26%
ROE -117.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.63%
ROA(5y)-35.6%
ROE(3y)-29.72%
ROE(5y)-43.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.47%
Cap/Sales 0.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.03
Quick Ratio 12.88
Altman-Z 11.07
F-Score2
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)2.09%
Cap/Depr(5y)5.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-193.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.11%
EPS Next Y-149.3%
EPS Next 2Y34.91%
EPS Next 3Y67.95%
EPS Next 5Y39.87%
Revenue 1Y (TTM)1122.61%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-144.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-139.65%
EBIT Next 3Y62.2%
EBIT Next 5YN/A
FCF growth 1Y-49.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.44%
OCF growth 3YN/A
OCF growth 5YN/A